Interleukin 1 is a key driver of inflammatory bowel disease-demonstration in a murine IL-1Ra knockout model by Le Maitre, Christine Lyn et al.
Interleukin 1 is a key driver of inflammatory bowel disease-
demonstration in a murine IL-1Ra knockout model
LE MAITRE, Christine Lyn <http://orcid.org/0000-0003-4489-7107>, DOSH, 
Rasha, JORDAN-MAHY, Nichola and SAMMON, Chris
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/24681/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
LE MAITRE, Christine Lyn, DOSH, Rasha, JORDAN-MAHY, Nichola and SAMMON, 
Chris (2019). Interleukin 1 is a key driver of inflammatory bowel disease-
demonstration in a murine IL-1Ra knockout model. Oncotarget. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
Oncotarget3559www.oncotarget.com
Interleukin 1 is a key driver of inflammatory bowel disease-
demonstration in a murine IL-1Ra knockout model
Rasha H. Dosh1,3, Nicola Jordan-Mahy1, Christopher Sammon2 and Christine Le 
Maitre1
1Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK
2Materials and Engineering Research Institute, Sheffield Hallam University, Sheffield, UK
3Department of Anatomy and Histology, Faculty of Medicine, University of Kufa, Kufa, Iraq
Correspondence to: Christine Le Maitre, email: c.lemaitre@shu.ac.uk
Keywords: IL-1Ra deficient; inflammatory bowel disease; pro-inflammatory cytokines; matrix-degrading enzymes; intestinal enzymes
Received: October 23, 2018     Accepted: April 03, 2019    Published: May 28, 2019
Copyright: Dosh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
Interleukin 1 (IL-1) is an important mediator of inflammation and tissue damage 
in inflammatory bowel disease (IBD). The balance between IL-1 and IL-1Ra as a natural 
inhibitor plays a vital role in a variety of diseases. Here, we investigated whether 
changes seen during IBD are induced spontaneously in mice lacking a functional IL-
1rn gene. Histological staining was performed on the jejunum and ileum of BALB/c 
IL-1rn+/+ and IL-1rn-/- mice to characterize crypt-villus height, villus width, and 
number of goblet cells per villus. Pro-inflammatory cytokines, immune cell infiltration 
and matrix-degrading enzymes, together with the production of intestinal enzymes 
and the integrity of tight and adherent junction proteins were determined using 
immunohistochemistry. In the small intestine of BALB/c IL-1rn-/- mice the villus heights 
were significantly reduced; and in the ileum this was accompanied by a decrease in 
villi width. There was also an increase in goblet cell number and mucin production 
compared to wild-type mice. IL-1α and IL-1β immunopositivity were increased, whilst 
IL-1R1 expression was decreased in IL-1rn-/- mice. IL-15 and TNFα were also increased 
in older IL-1rn-/-  mice. Increased polymorphonuclear and macrophage infiltration were 
seen in IL-1rn-/- mice, whilst expression of matrix-degrading enzymes and digestive 
enzymes were unchanged, except for dipeptidyl peptidase IV which was increased 
in younger IL-1rn-/- mice compared to wild type mice. The expression of tight and 
adhesion junctions were also dramatically decreased in IL-1rn-/- mice. In conclusion, IL-
1rn-/- mice developed spontaneous abnormalities which displayed features associated 
with IBD, demonstrating a clear role for IL-1 in IBD.
INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic 
autoimmune disease characterised by inflammation of 
the gastrointestinal tract and can be divided into two 
main types. Crohn’s disease (CD), which affects any 
part of the gastrointestinal tract especially the terminal 
ileum and colon; and ulcerative colitis (UC) which affects 
the rectum and colon [1]. Although the pathogenesis of 
IBD is not fully understood, IBD is thought to be caused 
by an imbalance between pro- and anti-inflammatory 
cytokines in local tissues which leads to inflammation and 
malfunction of the barriers in the intestinal tissue.
Interleukin 1 (IL-1) is a key mediator of innate 
immunity and inflammation which results in tissue 
damage in IBD. An imbalance between IL-1 and IL-
1Ra has been shown in the inflamed mucosa of patients 
with IBD where the levels of IL-1 and IL-Ra were 
increased, but importantly the ratio of IL-1Ra to IL-1 
was significantly decreased compared with controls 
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[1, 2]. During Crohn's disease, IL-1β is significantly raised 
and there is a positive correlation between the severity of 
mucosal inflammation and the levels of IL-1β [3]. It can 
also result in apoptosis of epithelial cells causing tissue 
damage and barrier dysfunction. Subsequently, the role of 
IL-1Ra in disease progression has been studied in various 
experimental animal models of IBD [4–6].
In the SAMP/YiT experimental mice model, there 
was an increase in Th-1 activity which mediates intestinal 
inflammation, and there was a spontaneous appearance 
of chronic ileitis which was similar in appearance to 
Crohn's disease due to increased intestinal paracellular 
permeability [7, 8]. This chronic ileitis is characterised 
by intestinal inflammation, having mononuclear and 
polymorphonuclear infiltration of the lamina propria; plus 
hyperplasia of paneth and goblet cells [9].
Although studies have reported that an imbalance 
between IL-1 and IL-1Ra contributes to inflammation in the 
large intestine in patients of IBD and in experimental animal 
models [1, 10, 11], whether this is a causative factor is 
unclear. Here, the histological changes in the small intestine 
of IL-1Ra knockout mice were investigated to assess the 
expression of pro-inflammatory cytokines, infiltration 
of immune cells, matrix-degrading enzymes, junctional 
proteins, and digestive enzymes in the small intestine of IL-
1Ra knockout mice compared to wild-type mice in two age 
groups in order to determine whether features associated 
with IBD could be induced spontaneously in the small 
intestine by the removal of IL-1Ra in mice.
RESULTS
Histological analysis
Crypt-villus axis height and villus width
In the jejunum, there was a significant decrease 
in height of crypt-villus axis of the 155-185 day old 
IL-1rn-/- mice compared with age-matched WT mice 
(~7% decrease)(P≤0.05) (Figure 1). However, the crypt-
villus height of the jejunum was significantly greater in 
the 155-185 day old compared to the 55-day old mice 
in WT groups (P≤0.05). The width of the villus at half 
crypt-villus axis was unchanged in all groups (Figure 1). 
Morphology of jejunal villi of 155-185 day old IL-1rn-/- 
mice revealed moderate epithelial damage with separation 
of the columnar epithelia from the lamina propria within 
the villi and the formation of large spaces between the 
crypt base and the muscularis mucosa in the 55-day old 
IL-1rn-/- mice (Figure 1).
In the ileum, there was a significant decrease in 
the crypt-villus axis height of both the 55-day old (~7% 
decrease) and 155-185 day old (~13% decrease) IL-1rn-/- 
mice compared with WT mice (P≤0.05) and a significant 
decreased in 155-185 day old IL-1rn-/- mice compared with 
55-day old IL-1rn-/- mice (P≤0.05). In contrast, the crypt-
villus axis height was significantly increased in 155-185 
day old IL-1rn+/+ mice compared with 55-day IL-1rn+/+ 
mice (Figure 2). A significant decrease was seen in villus 
width in 155-185 day old IL-1rn-/- mice compared with 
155-185 day old WT mice (~15% decrease) and 55-day IL-
1rn-/- mice (P≤0.05). While villus width in the ileum was 
significantly increased in 155-185 day WT mice compared 
with 55-day old WT mice (P≤0.05) (Figure 2). Once again 
there was a separation of the columnar epithelium from the 
lamina propria within the villi and the formation of large 
spaces between the crypt base and the muscularis mucosa 
in the 155-185 day old IL-1rn-/- mice (Figure 2).
Number of goblet cells per crypt-villus axis
In the jejunum and ileum, there was a significant 
increase in the number of goblet cells per crypt-villus 
axis in all IL-1rn-/- mice groups compared with WT 
mice (P≤0.05). Furthermore, in the jejunum, there was a 
significant increase in the number of goblet cells per crypt-
villus axis in 155-185 day old WT compared to 55 day 
old WT mice (P≤0.05) (Figure 3A & 3B). Moderate and 
intense PAS (pink) staining was observed in 55 day old 
WT and IL-1rn -/-  mice and intense alcian blue staining 
was observed in 155-185 day old WT and IL-1rn -/- mice. 
This indicated the presence of neutral mucins in younger 
mice, and acidic mucins in older mice in both the jejunum 
and the ileum (Figure 3A & 3B).
Assessment of pro-inflammatory cytokine expression 
and localization
Across the small intestine (jejunum and ileum), 
the expression of pro-inflammatory cytokine: IL-1α was 
highly expressed in both the villi and crypts. There was 
a significant increase in IL-1α immunopositivity in 155-
185 day old IL-1rn-/- mice, compared with WT mice and 
55 day IL-1rn-/- mice (P≤0.05) (Supplementary Figure 1A 
and Figure 4A & 4B). Whilst high levels of IL-1α were 
seen in all mice, only low levels of immunopositivity were 
seen in WT mice with a significant increase in IL-1β in the 
55 day old and 155-185 day old IL-1rn-/- mice, compared 
with WT mice (P≤0.05) (Supplementary Figure 1B and 
Figure 4C & 4D). The expression of IL-1R1 was primarily 
located in villi (Supplementary Figure 1C and Figure 4E 
& 4F); however, there was a significant decrease in IL-
1R1 expression in both the 55 day old and 155-185 day 
old IL-1rn-/- mice compared with WT mice (P≤0.05). 
IL-1R1 expression in 155-185 day old WT and 155-185 
day old IL-1rn-/- mice were significantly lower than those 
seen in the 55 day old WT and 55 day old IL-1rn-/- mice, 
respectively (P≤0.05) (Supplementary Figure 1C and 
Figure 4E & 4F).
IL-15 expression was observed only at low levels 
in the 55 day old IL-1rn-/- mice, and localized in both the 
villi and crypts, but significantly increased in the 155-185 
day old IL-1rn-/- mice, compared with WT mice (P≤0.05) 
(Supplementary Figure 2A and Figure 5A & 5B). TNFα 
expression was also observed at low levels in the 55 day 
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old IL-1rn-/- mice. TNFα was localized in the villi of the 
jejunum and in the submucosa of the ileum, and was 
expressed at greater levels than in the WT mice. Whereas 
TNFα expression was significantly increased in the 155-
185 day old IL-1rn-/- mice, where immunopositive cells 
were localized within the villi, crypts, and the submucosa 
of the jejunum and ileum, and was significantly greater 
than that seen in the WT mice (P≤0.05) (Supplementary 
Figure 2A and Figure 5C & 5D).
Figure 1: Histological analysis and morphology of the intact well-oriented crypt-villus axis heights and villus widths 
of Jejunum in the 55 day old IL-1rn-/- mice and 155-185 day old IL-1rn-/- mice compared to age-matched wild-type 
mice. Stained with H&E. Black arrows indicate moderate epithelial damage in 155-185 day old IL-1rn-/- mice, enlarged space between the 
crypt base and the muscularis mucosa. *P ≤ 0.05. Scale bar = 100 µm.
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The number of infiltrated polymorphonuclear 
(PMN) cells in the lamina propria were significantly 
increased in the 55 day old and 155-185 day old 
IL-1rn-/- mice compared with WT mice (P≤0.05) 
(Supplementary Figure 3A and Figure 6A & 6B). Crypt 
abscesses were observed in the ileum of 155-185 day 
Figure 2: Histological analysis and morphology of the intact well-oriented crypt-villus axis heights and villus widths of 
Ileum in the 55 day old IL-1rn-/- mice and 155-185 day old IL-1rn-/- mice compared to age-matched wild-type mice. Stained 
with H&E. Black arrows indicate enlarged space between the crypt base and the muscularis mucosa. *P ≤ 0.05. Scale bar = 100 µm.
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old IL-1rn-/- mice. Here, PMN cells were seen to cluster 
together within the lamina propria of the villi of 55 day 
old IL-1rn-/- mice and in the crypts of the 155-185 day 
old IL-1rn-/- mice. The number of macrophages was 
significantly increased in 55 day old and 155-185 day 
old IL-1rn-/- mice compared with WT mice (P≤0.05). 
Similar distributions were seen throughout the lamina 
propria of the villi in the young and old IL-1rn-/- mice in 
the jejunum and ileum (Supplementary Figure 3B and 
Figure 6C & 6D).
Figure 3: Histological analysis and morphology of goblet cells per intact well-oriented crypt-villus axis of the (A) Jejunum 
and (B) Ileum of 55 day old and 155-185 days old IL-1rn-/- mice compared with age-matched WT mic, stained with AB-PAS. 
*P ≤ 0.05. Scale bar = 100 µm.
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Assessment of degrading enzyme expression and 
localization
Although MMP2 expression was higher in both 
the 55 day old and 155-185 day old IL-1rn-/- mice than 
WT mice, this failed to reach significance. In 55 day old 
and 155-185 day old IL-1rn-/- mice, MMP2 was highly 
expressed in the villi, crypts and muscularis mucosa 
(Supplementary Figure 4A and Figure 7A and 7B).
MMP9 expression was limited in all groups; its 
expression was higher in the submucosa of the ileum than 
the jejunum in the 55 day old WT, IL-1rn-/-  mice and in 155-
185 day old WT mice (Supplementary Figure 4B and Figure 
7C and 7D). Although ADAMTS1 was highly expressed 
in the jejunum and ileum of the IL-1rn-/- mice, there were 
no significant differences between age and genotypes 
(Supplementary Figure 4C and Figure 7E and 7F).
Assessment of enterocyte polarity and cell-cell 
adherence
ZO-1 and E-cadherin were expressed from the surface of 
the villi down to crypts in WT mice. The level of expression of 
Figure 4: Immunohistochemistry staining of the expression and localization of pro-inflammatory cytokines: IL-1α (A) IL-
1β (C) IL-1RI (E) show the immunopositive intensity quantification across the small intestinal architecture. (B, D) and (F) 
showing the immunopositive staining in the ileum of the 55 day old and 155-185 day old IL-1rn-/- mice compared with WT mice. Cell nuclei 
were stained with haematoxylin (blue). Black arrows indicate immunopositivity. *P ≤ 0.05. Scale bar = 100 µm.
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Figure 5: Immunohistochemistry staining of the expression and localization of pro-inflammatory cytokines: IL-15 (A) 
TNFα (C) show the immunopositive intensity quantification across the small intestinal architecture. (B and D) showing 
immunopositive staining in the ileum of the 55 day old and 155-185 day old IL-1rn-/- mice compared with WT mice. Cell nuclei were 
stained with haematoxylin (blue). Black arrows indicate immunopositivity. *P ≤ 0.05. Scale bar = 100 µm.
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both ZO-1 and E-cadherin was significantly decreased in both 
the 55 day old and 155-185 day old IL-1rn-/- mice compared 
to age-matched WT controls (P≤0.05) (Supplementary Figure 
5A & 5B and Figure 8A, 8B, 8C, 8D). In the jejunum, ZO-1 
expression was localized on villi tips only in the 155-185 day 
old IL-1rn-/- mice, which was significantly less than that seen in 
younger 55 day old of IL-1rn-/- and WT mice (Supplementary 
Figure 5A). In contrast, ZO-1 was uniformly expressed at the 
cell surface of the entire villi in the ileum and was comparable 
to that seen in WT mice (Figure 8A and 8B). E-cadherin 
immunopositivity was lost in the jejunum and ileum of 
155-185 day old of IL-1rn-/- mice compared to WT mice 
(Supplementary Figure 5B and Figure 8C & 8D).
Assessment of digestive enzyme expression and 
localization
ALP expression was weak in all mice; however, 
specific ALP immunopositivity was seen on the brush 
border of the enterocytes and in the lamina propria cells 
(Supplementary Figure 6A and Figure 9A & 9B).
Sucrase-isomaltase expression was localized to the 
apical epithelial surface and was highly expressed in all 
mice (Supplementary Figure 6B and Figure 9C & 9D). DPP 
IV expression was increased in 55-day old IL-1rn-/- mice 
compared with WT mice (P≤0.05), this expression was 
localized on the enterocyte surface and in the lamina propria 
cells (Supplementary Figure 6C and Figure 9E & 9F). 
Figure 6: Immunohistochemistry staining of the infiltrated cells: Polymorphonuclear cells (PMNs) (A and B) and macrophage 
cells (C and D) into the lamina propria of the intact well oriented crypt-villus axis in the ileum of the 55 day old and 155-
185 day old IL-1rn-/- mice compared with WT mice. Cell nuclei were stained with haematoxylin (blue). Black arrows indicate 
immunopositivity. *P ≤ 0.05. Scale bar = 25 µm.
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DISCUSSION
The balance between IL-1 and IL-1Ra as 
an endogenous inhibitor plays an essential role in 
stimulation and regulation of inflammation in IBD [1], 
however, whether IL-1 is an important causative factor 
in IBD or purely a result of inflammation is not currently 
understood. Thus, this study investigated whether 
changes seen during IBD could be induced spontaneously 
by the removal of IL-1Ra in mice that lack a functional 
IL-1rn gene. In IL-1rn-/- mice, the villi were shown to be 
shorter in the jejunum, while shorter and thinner in the 
ileum, within the ileum of older mice a 13% decrease in 
height and 15% decrease in width was observed. These 
large changes would result in a substantial decrease in 
digestive and absorptive area, and thus be expected to 
lead to defiency in nutrient uptake. This blunting of the 
villi is a common microscopic feature of IBD and has 
been observed in patients with Crohn's disease in both 
the jejunum and the ileum [12]. In contrast, in WT mice 
Figure 7: Immunohistochemistry staining of the expression and localization of degrading enzymes: MMP2 (A) MMP9 (C) 
ADAMTS1 (E) show the immunopositive intensity quantification across the small intestinal architecture. (B, D and F) showing 
the immunopositive staining in the ileum of the 55-day old and 155-185 day old IL-1rn-/- mice compared with WT mice. Cell nuclei were 
stained with haematoxylin (blue). Black arrows indicate immunopositivity. Scale bar = 100 µm.
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Figure 8: Immunohistochemistry staining of the expression and localization of junctional proteins: ZO-1 (A) E-cadherin (C) 
showing the immunopositive intensity quantification across the small intestinal architecture. (B and D) show the immunopositive 
staining in the ileum of the 55 day old and 155-185 day old IL-1rn-/- mice compared with WT mice. Cell nuclei were stained with 
haematoxylin (blue). Black arrow sindicate immunopositivity. *P ≤ 0.05. Scale bar = 100 µm.
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the villus height and width were shown to be comparable 
to those of wild-type C57BL/6J mice of a similar age 
and region of the small intestine [13]. As seen in the WT 
mice, there was a decrease in height and width along a 
proximal-distal gradient of the small intestine. Similarly 
to these findings, in a wild-type C57BL/6J mice model a 
comparison of old and young mice, showed an increase 
in villi height with age, whilst the villi width was 
unchanged [13].
Physiologically intestinal goblet cells secrete 
large amounts of mucus, which coat and cover the 
intestinal villi. This mucus plays an important role in the 
maintenance of the intestinal mucosal barrier and creates 
a milieu in which digestion and absorption take place 
[14]. Here, a substantial increase in the number of goblet 
cells per villus in both jejunum and ileum of IL-1rn-/- mice 
compared with WT mice was observed which reached 22-
29% more goblet cells in the ileum. This large increase 
Figure 9: Immunohistochemistry staining of the expression and localization of the digestive enzymes: ALP (A) SI (C) and 
DPP IV (E) show the immunopositive intensity quantification across the small intestinal architecture. (B, D and F) showing 
the immunopositive staining in the ileum of the 55 day old and 155-185 day old IL-1rn-/- mice compared with WT mice. Cell nuclei were 
stained with haematoxylin (blue). Black arrows indicate immunopositivity. *P ≤ 0.05. Scale bar = 100 µm.
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in goblet cells which accompanies the inflammatory 
process is believed to be caused by increased expression 
of the transcription factors: Hath1 (a basic helix-loop-helix 
(bHLH) transcription factor) and Klupper like factor 4 
(KLF4), which are essential for goblet cell differentiation 
[15]. This inflammatory process is believed to drive the 
increase in goblet cell differentiation, which is observed 
in Crohn's disease patients [15]. However, it is important 
to note that this increase in goblet cells is not found in 
all Crohn's disease patients, or throughout the whole 
gastrointestinal tract [16].
Maintenance of intestinal homeostasis is regulated 
by epithelial barrier integrity [17]. Diffusion of the 
luminal materials into lamina propria promotes a local 
inflammatory response causing release of proinflammatory 
cytokines, release of MMPs, and epithelial degradation 
and inflammation [18]. Expression of pro-inflammatory 
cytokines: IL-1α, IL-1β, TNFα, and IL-15 were increased in 
IL-1rn-/- mice, and these results are in agreement with those 
obtained from patients with Crohn's disease [19]. IL-1α 
and IL-1β are also expressed in human intestinal epithelial 
cells [20]. IL-1α is released when these human intestinal 
cells are damaged or destroyed, and IL-1α was commonly 
detected in the epithelium of IBD, released from necrotic 
intestinal epithelial cells and plays a crucial role in intestinal 
inflammation by inducing human intestinal fibroblasts to 
produce IL-6 and IL-8 [21]. The high concentrations of 
IL-1β in the intestine of patients with Crohn's disease are 
mainly attributed to local mononuclear cell infiltration 
[22], which were also observed in this model. Increased 
production of IL-1β and TNFα in inflamed Crohn's disease 
mucosa induces the synthesis of IL-8, which is an effective 
neutrophil chemoattractant [23]. These findings agree 
with previous work, which showed increased numbers of 
TNFα positive cells in the lamina propria and submucosa 
of patients with Crohn's disease. Furthermore, TNFα 
produced by subepithelial macrophages has been shown to 
contribute to decreased epithelial integrity [24]. TNFα acts 
as an important mediator of inflammation through MAPK 
and NF-κB activation, increasing cell proliferation and 
altering epithelial barrier permeability [25]. The production 
of TNFα is also high in cultured mucosal mononuclear cells 
from Crohn's disease patients [26]. However, in contrast a 
previous study observed no differences in TNFα mRNA 
expression between control and IBD mucosal biopsies [27].
IL-1RI is expressed on many cell types including 
T cells, fibroblasts, and intestinal epithelial cells. Despite 
the increased expression of IL-1β in the IL-1rn-/- mice, the 
expression of IL-1R1 was reduced; this could suggest a 
negative feedback loop decreasing expression of IL-1RI in 
the presence of uncontrolled IL-1 production. This agrees 
with a previous study, which showed IL-1β and TNFα 
treatment downregulated the expression of mRNA IL-1RI 
in rat intestinal epithelial cells (IEC-6) [28]. Similarly, 
IL-1β treatment was also shown to downregulate IL-1RI 
protein in retinal endothelial cells (TR-iBRB2) [29]. This 
is contrary to previous study, in which an increase in IL-
1β induced chronic intestinal inflammation in mice and an 
increase in IL-17A-secreting innate lymphoid cells which 
express high levels of IL-1R1 [30]. These differences may 
be a result of the different levels of inflammation seen in 
these models. Here, increased expression of IL-15 was 
seen in IL-1rn-/- mice, this is in agreement with Liu et al 
(2000), who showed increased expression of IL-15 by 
macrophages in the inflamed ileum of patients with Crohn's 
disease and that IL-15 increased local T cell activation and 
induced proinflammatory cytokine production by T cells 
and macrophages. The presence of polymorphonuclear 
cells and mononuclear cells play an important role in the 
augmentation of inflammation and tissue damage in IBD 
[31]. Increased infiltration of these CD11b and CD68 
positive cells into the lamina propria were observed in 
IL-1rn-/- mice compared with WT mice. These findings 
are in agreement with previous findings which showed 
increased numbers of these cells in the inflamed mucosa 
of IBD patients [32]. Infiltration of immune cells such as 
macrophages and lymphocytes in the lamina propria is 
an important aspect of IBD, especially Crohn's disease, 
even in the lack of noticeable morphological, clinical, and 
endoscopic indication of inflammation. This is thought 
to be due to an increased demand of macrophages within 
the inflamed intestine [33]. Functional assessment of this 
increased inflammatory response such as calprotectin 
measurement in stool samples would have been a useful 
assessment, however unfortunately these samples were not 
available in this study.
MMPs and ADAMTS1 expression were not 
significantly altered in IL-1rn-/- mice. MMPs have been 
demonstrated to be induced in several pathological 
conditions of IBD and play a key role in regulating the 
pathophysiology of IBD [34]. The main action of MMPs 
is to degrade extracellular matrix proteins. Active MMP2 
and MMP9 play an important role in cell migration and 
cytokine stimulation. Indeed neutrophil infiltration has 
been shown to be induced by upregulation of MMP9 in 
murine inflamed intestine [35]. Furthermore, stromal 
cells play an important role in intestinal inflammation and 
the pathogenesis of IBD. These cells secrete MMP2 and 
MMP9 [36]; and MMP9 is produced by human colonic 
epithelium during IBD [37]. In addition, infiltrating 
macrophages and neutrophils are the main source of 
MMP9 in human IBD [38]. Overexpression of MMP9 
has been shown to cause a reduction in the differentiation 
of progenitor cells to goblet cells and consequently 
decreased MUC2 expression, which leads to decreases in 
the protective mucin barrier in colonic epithelium [35].
The maintenance of epithelial barrier function 
and control of paracellular permeability are regulated 
by tight junction proteins [39]. Epithelial disruption and 
decrease in tight junctions that lead to increased intestinal 
permeability are the common features of Crohn's disease 
[40]. Decreased expression of ZO-1 and loss of E-cadherin 
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expression were observed in IL-1rn-/- mice, suggesting a 
dysfunctional and leaky epithelial barrier, and separation 
of the mucosa and lamina propria. Inflammatory cytokines 
are known to affect epithelial junctional complexes, 
causing barrier dysfunction and increased epithelial 
permeability [39]. A previous study showed that a tight 
junction disorder has been found in the epithelial cells 
of the terminal ileum from patients with Crohn's disease 
[41]. In addition, it has been shown that IL-1β and TNFα 
induced defects in intestinal epithelial tight junctions 
resulting in increased intestinal permeability [42].
ALP plays an essential role in maintaining small 
intestinal homeostasis and has been shown to prevent 
the activation of NF-kB, thus inhibiting release of pro-
inflammatory cytokines. Decreased activity of ALP could 
increase intestinal inflammation [43], and intestinal 
epithelial dysfunction in IBD patients has been attributed 
to lower intestinal expression and activity of ALP [44]. 
Surprisingly, the expression of digestive enzymes were 
not altered in IL-1rn-/- mice compared with WT mice. This 
demonstrated the resilience of the intestine to maintain 
function even during severe inflammation. SI expression 
was unchanged, which is contrary to decreased gene 
expression of SI in villus enterocytes seen in the ileum 
of patients with Crohn's disease [45]. DPP IV expression, 
however, was significantly increased in the young IL-
1rn-/-  mice, but not the older IL-1rn-/- mice compared to 
WT mice. A similar loss of DPPIV activity has been seen 
in the serum of patients with IBD [46].
MATERIALS AND METHODS
IL-1rn-/- BALB/c mice
IL-1rntm1Nick deficient mice (IL-1rn-/-) have been 
described previously [47]. All mice were housed behind 
positive pressure barriers and were reared under UK Home 
Office licenses. All materials were supplied sterile and 
certified pathogen free. This work was approved by the 
University of Sheffield ethical review panel. Formalin-
fixed mice were a kind gift from Dr. Martin Nicklin, 
University of Sheffield. To ensure that experimental 
procedures aligned with the 3Rs principle, initial work 
was completed on n=4 and statistical analysis performed, 
as statistically significant differences were seen in n=4 
it was not deemed ethically appropriate nor necessary to 
increase the number of animals utilised.
Tissue preparation and histological assessment
The entire jejunum and ileum portions of small 
intestine were dissected from BALB/c IL-1rn-/- knockout 
mice aged 50-55 days (n=4) and 155-185 day old (n=4), 
together with age-matched BALB/c wild-type (WT) 
controls (n=4 at each age). Following dissection, tissues 
were rinsed in PBS and fixed in 10% v/v formalin for 24 
h and then transferred to 70% v/v ethanol. Tissues were 
processed and embedded in paraffin wax. Five-micron 
sections were cut and mounted onto positively charged 
Table 1: Target antibodies used for IHC, their optimal concentration and antigen retrieval methods
Antibody Clonality Dilution Antigen 
retrieval
Supplier Catalogue No.
IL-1α Rabbit polyclonal 1:100 Heat Abcam ab7632
IL-1β Rabbit polyclonal 1:100 Heat Abcam ab9722
IL-1R1 Rabbit polyclonal 1:100 Enzyme Abcam ab106278
IL-15 Rabbit polyclonal 1:50 Enzyme Abcam ab7213
TNFα Rabbit polyclonal 1:50 Enzyme Abcam ab6671
CD11b Goat polyclonal 1:600 None Abcam ab62817
CD68 Mouse monoclonal 1:200 Enzyme Abcam ab955
MMP2 Rabbit polyclonal 1:800 Enzyme Abcam ab37150
MMP9 Rabbit polyclonal 1:25 Heat Abcam ab38898
ADAMTS1 Rabbit polyclonal 1:200 Enzyme Abcam ab39194
ZO-1 Rabbit polyclonal 1:50 Enzyme Abcam ab217334
E-cadherin Mouse monoclonal 1:200 Heat Abcam ab76055
ALP Rabbit monoclonal 1:200 Heat Abcam ab108337
SI Mouse monoclonal 1:50 Heat Santa Cruz sc-393470
DPP I Mouse monoclonal 1:50 Enzyme Abcam ab119346
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slides (Leica Microsystem Milton Keynes, UK). Sections 
were deparaffinised in Sub-X and rehydrated in industrial 
methylated spirits (IMS) prior to rehydration in distilled 
water. Sections were then stained with either: Haematoxylin 
and Eosin; Mayer's Haematoxylin (Leica Microsystem, 
Milton Keynes, UK) for 2 min rinsed in water for 5 min and 
immersed in Eosin (Leica Microsystem, Milton Keynes, 
UK) for 1 min; or Alcian Blue/Periodic acid Schiff's (PAS): 
1% w/v Alcian Blue (PH 2.5) (Sigma-Aldrich, Poole, UK) 
in 3% (v/v) acetic acid (Sigma-Aldrich, Poole, UK) for 
30 min and immersed in 0.5% (w/v) Periodic acid for 10 
min and rinsed three times in deionised water. Slides were 
then immersed in Schiff reagent (Merck KGaA, Germany) 
for 10 min, and then rinsed three times with deionised 
water. Following staining, sections were dehydrated in 
IMS, cleared with Sub-X and mounted in Pertex (Leica 
Microsystem, Milton Keynes, UK). The slides were 
examined with an Olympus BX 51 microscope and images 
captured by the digital camera and Capture Pro OEM V8.0 
software (Media Cybernetics, Buckinghamshire, UK).
The tissue morphology was assessed using the 
Capture Pro OEM V8.0 software measurement tools as 
follows:
Crypt-villus height and villus width
Twenty well oriented crypt-villus axes height and 
villus width at half-axis height in longitudinal tissue 
sections were measured in the jejunum and ileum of all 
mice, from each age range and genotype.
Goblet cells per crypt-villus axis
The numbers of goblet cells within twenty well 
oriented crypt-villus axes were counted in the jejunum 
and ileum of all mice from each age range and genotype.
Immunohistochemical assessment
Pro-inflammatory cytokine expression and immune 
cell infiltration
The expression of pro-inflammatory cytokines 
IL-1α, IL-1β, and their receptor: IL-1RI; IL-15, and 
TNFα were investigated by immunohistochemistry. In 
addition, the number of immune cells which infiltrated into 
lamina propria of crypt-villus axis was determined using 
immunohistochemistry of polymorphonuclear cell marker: 
CD11b and macrophage marker CD68, in the jejunum and 
ileum of three randomly selected mice, from each age range 
and genotype.
Matrix-degrading enzyme expression
The expression of matrix-degrading enzymes: 
MMP2, MMP9, and ADAMTS1 were assessed in the 
jejunum and ileum of three randomly selected mice, from 
each age range and genotype using immunohistochemistry.
Polarity of enterocytes and digestive enzyme expression
The expression of tight junction proteins Zonulin 
1 (ZO-1) and adherent junction protein E-cadherin, 
were assessed alongside digestive enzymes: alkaline 
phosphatase (ALP), sucrase-isomaltase (SI), and 
dipeptidyl peptidase IV (DPP IV) in the jejunum and ileum 
of three randomly selected mice, from each age range and 
genotype.
Immunohistochemistry was performed as described 
previously [48]. Briefly, 5 µm sections were de-waxed, 
rehydrated, and endogenous peroxidase blocked using 
hydrogen peroxide (Sigma-Aldrich, Poole UK). After 
washing in Tris-buffered saline (TBS) (20mM Tris, 
150mM sodium chloride, pH 7.5), tissue sections were 
subjected to antigen retrieval sections were subjected to 
an appropriate antigen retrieval method, specific to the 
antibodies investigated (Table 1). Following this sections 
were washed in TBS. Then nonspecific binding sites were 
blocked at room temperature for 90 min with 25% (w/v) 
serum (Abcam, Cambridge, UK) in 1% (w/v) bovine 
serum albumin in TBS. Sections were incubated overnight 
at 4°C with appropriate primary antibody (Table 1).
For each immunohistochemistry method, a negative 
control was performed, replacing the primary antibody 
with either rabbit or mouse IgG (Abcam, Cambridge, 
UK) as appropriate, at a concentration equal to that of the 
primary antibody. Sections were washed in TBS and then 
incubated in 1:500 dilution of an appropriate biotinylated 
secondary antibody for 30 min at room temperature. Binding 
of the secondary antibody was visualised after exposure to 
horseradish peroxidase (HRP) streptavidin-biotin complex 
(Vector Laboratories, Peterborough, UK) for 30 min. 
Sections were washed in TBS, and treated with 0.08% (v/v) 
hydrogen peroxide in 0.65mg/ml 3, 3′-diaminobenzidine 
tetrahydrochloride (Sigma-Aldrich, Poole, UK) in TBS 
for 20 min. Sections were counterstained with Mayer’s 
haematoxylin, dehydrated, cleared and mounted in Pertex. 
Immunohistochemical staining were examined with an 
Olympus BX51 microscope and images captured by 
digital camera and Capture Pro OEM v8.0 software (Media 
Cybernetics, Buckinghamshire, UK). Immunopositive 
intensity across the small intestine architecture was 
independently semi-quantified by two assessors (CLM 
and NJM), blinded to animal genotype and age. A scale of 
0 to 6 was utilised where 0 was no immunopositivity and 
6 signifies maximum immunopositivity. The number of 
immunopositive (CD11b and CD68) immune cells were 
counted within twenty well oriented crypt-villus axes of 
each of three randomly selected mice, from each age range 
and genotype.
Statistical analysis
Data was plotted using GraphPad Prism V6.0. 
Crypt-villus axes height and villus width were assessed 
for normality using Stats Direct program and found to 
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be non-parametric and therefore statistical comparisons 
were performed by Kruskal-Wallis with a pairwise 
comparison (Conover-Inman) between ages and 
genotypes. Statistical significance was set at P ≤ 0.05, 
for statistical analysis the mean villi height, width 
and goblet cells per villi per mouse were utilised for 
statistical analysis. All replicates are shown with the 
median values for each mouse to demonstrate clearly the 
spread of replicates.
CONCLUSIONS
IL-1Ra deficient mice (IL-1rn-/-) induced spontaneous 
intestinal inflammation which provides an effective 
approach to display features associated with IBD. Old 
IL-1rn-/- mice demonstrated a higher inflammatory 
response than young IL-1rn-/- mice. This model delivers 
evidence for a role of the imbalance between IL-1 and 
IL-1Ra in the pathogenesis of IBD and could provide a 
useful model for testing new therapies.
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